Published: January 03, 2013
Amakem Secures EUR1.4M Grant to Apply its Localized Drug Action Technology in Inflammatory Bowel Diseases (IBD)
DIEPENBEEK, Belgium, January 3, 2013 /PRNewswire/ --
Amakem NV, a kinase platform company focusing on ophthalmology, today announces it has
secured a EUR1.4M grant from the Flemish Agency for Innovation by Science and Technology
(IWT), to apply its Localized Drug Action technology to the discovery and development of
novel kinase inhibitor-based therapies for Inflammatory Bowel Diseases (IBD).
IBD is a chronic, relapsing inflammatory disease of the gastrointestinal tract
To read the complete release at NewsBlaze,
Amakem Secures EUR1.4M Grant to Apply its Localized Drug Action Technology in Inflammatory Bowel Diseases (IBD),
Related PRNewswire Releases News
Emergency Deployment Supported by Mars Petcare US, Rescue Bank®, Banfield Pet Hospital, Zoetis, Lois Pope, MuttNation Foundation, and Caring People Across America
Among the select few physicians honored with the prestigious Patients' Choice Award this year is Dr. Alfred Soto.
The University of Texas at Arlington is one of six universities nationwide to be named a 'Next Generation University' in a new study published by the New America Foundation, a nonprofit organization focused on public policy issues.
Independent Living Centers Offer Individuals a Safe Environment with Solutions
International law firm Greenberg Traurig represented Danone in connection with an agreement to acquire an equity interest of over 90% in Happy Family, a U.S. organic baby-food company. The transaction will strengthen Danone's fast-growing infant-...
In a statement released today, the Center for Democracy in the Americas is criticizing the Obama administration for 'knuckling under to Congressional pressure' and raising the budget for USAID's regime change activities in Cuba.